

Chronic Gout Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

The market size of Chronic Gout in the 7MM was found to be USD 2,405.3 Million in 2018, which is expected to grow by 2032.

LAS VEGAS, NEVADA, UNITED STATES, April 4, 2024 /EINPresswire.com/ -- DelveInsight's "Chronic Gout Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Chronic Gout, historical and forecasted epidemiology as well as the Chronic Gout market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Gout market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Chronic Gout Market Forecast](#)

Some of the key facts of the Chronic Gout Market Report:

The Chronic Gout market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

Key Chronic Gout Companies: Teijin Pharma, Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., Jiangsu Atom Bioscience and Pharmaceutical, ArthroSi Therapeutics, Selecta Biosciences, Shanton Pharma, and others

Key Chronic Gout Therapies: ABP 671, AR-882, TMX-049, Pegadricase-SVP, SAP 001, and others. As per DelveInsight, the total prevalent cases of Chronic Gout in the 7MM were 2,355,200+ in 2018.

The market size of Chronic Gout in the 7MM was found to be USD 2,405.3 Million in 2018, which is expected to grow by 2032.

According to the National Kidney Foundation, gout affects 8.3 million adults in the US, which includes 6.1 million men and 2.2 million women.

According to the article by Pisaniello et al. (2018), titled "Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study," prevalence of gout in the UK, Germany, Canada, US, and New Zealand have varied from 1.4% to 3.9%.

The Chronic Gout market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Gout pipeline products will significantly revolutionize the Chronic Gout market dynamics.

Chronic Gout Overview

Gout is a persistent condition marked by the accumulation of monosodium urate (MSU) crystals in the body. It often manifests as sudden, limited inflammation in the joints of the lower limbs. Over time, it leads to prolonged joint inflammation, resulting in pain both at rest and during movement. Hyperuricemia, or high levels of uric acid in the blood, is a major contributor to chronic gout. Elevated serum urate levels are associated with increased risks of gout attacks and more frequent flare-ups.

Chronic gout primarily presents with intense joint pain, accompanied by swelling, inflammation, and redness. A confirmed diagnosis of chronic gout requires laboratory confirmation of MSU crystals in the synovial fluid during episodes of acute joint inflammation. To aid in clinical decision-making and enhance patient care in primary and acute settings, a systematic review comparing the accuracy of various diagnostic tests for chronic gout against synovial fluid analysis, including physical examinations, serum uric acid levels, ultrasound, plain radiography, and dual-energy computed tomography (DECT), can be beneficial for both patients and healthcare providers.

Chronic Gout Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Gout Epidemiology Segmentation:

The Chronic Gout market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chronic Gout

Prevalent Cases of Chronic Gout by severity

Gender-specific Prevalence of Chronic Gout

Diagnosed Cases of Episodic and Chronic Chronic Gout

Download the report to understand which factors are driving Chronic Gout epidemiology trends @ [Chronic Gout Epidemiology Forecast](#)

Chronic Gout Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Gout market or expected to get launched during the study period. The analysis covers Chronic Gout market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs

based on market share.

The report also covers the Chronic Gout Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Gout Therapies

ABP 671

AR-882

TMX-049

Pegadricase-SVP

SAP 001

Key Companies

Teijin Pharma

Horizon Therapeutics

Sanwa Kagaku Kenkyusho Co. Ltd.

Jiangsu Atom Bioscience and Pharmaceutical

ArthroSi Therapeutics

Selecta Biosciences

Shanton Pharma

Discover more about therapies set to grab major Chronic Gout market share @ [Chronic Gout Treatment Landscape](#)

Chronic Gout Market Dynamics

The Chronic Gout market is experiencing a positive shift in growth due to the significant increase in gout incidence and prevalence in recent decades. Previously, treating gout in patients with concurrent metabolic syndrome and other comorbidities like renal impairment was challenging because of limited therapeutic options available in the market. However, the introduction of new medications such as febuxostat and pegloticase has led to significant advancements in Chronic Gout treatment in recent years. Additionally, several other drugs with well-founded mechanisms of action are currently in the development pipeline and are likely to be launched in the Chronic Gout market in the near future.

Despite these advancements, certain factors are hindering the growth of the Chronic Gout market. There is a general lack of knowledge and understanding about gout care among both patients and healthcare providers. This lack of awareness often results in underdiagnosis and undertreatment of gout, especially in individuals who do not fit the typical profile associated with

the condition, such as younger patients.

Scope of the Chronic Gout Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Chronic Gout Companies: Teijin Pharma, Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., Jiangsu Atom Bioscience and Pharmaceutical, ArthroSi Therapeutics, Selecta Biosciences, Shanton Pharma, and others

Key Chronic Gout Therapies: ABP 671, AR-882, TMX-049, Pegadricase-SVP, SAP 001, and others

Chronic Gout Therapeutic Assessment: Chronic Gout current marketed and Chronic Gout emerging therapies

Chronic Gout Market Dynamics: Chronic Gout market drivers and Chronic Gout market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Chronic Gout Unmet Needs, KOL's views, Analyst's views, Chronic Gout Market Access and Reimbursement

Table of Contents

1. Chronic Gout Market Report Introduction
2. Executive Summary for Chronic Gout
3. SWOT analysis of Chronic Gout
4. Chronic Gout Patient Share (%) Overview at a Glance
5. Chronic Gout Market Overview at a Glance
6. Chronic Gout Disease Background and Overview
7. Chronic Gout Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Gout
9. Chronic Gout Current Treatment and Medical Practices
10. Chronic Gout Unmet Needs
11. Chronic Gout Emerging Therapies
12. Chronic Gout Market Outlook
13. Country-Wise Chronic Gout Market Analysis (2019–2032)
14. Chronic Gout Market Access and Reimbursement of Therapies
15. Chronic Gout Market Drivers
16. Chronic Gout Market Barriers
17. Chronic Gout Appendix
18. Chronic Gout Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Chronic Gout Pipeline

"Chronic Gout Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Gout market. A detailed picture of the Chronic Gout pipeline landscape is provided, which includes the disease overview and Chronic Gout treatment guidelines.

Chronic Gout Epidemiology

DelveInsight's 'Chronic Gout Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Gout epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kritika Rehani

Email: info@delveinsight.com

Contact No.: +14699457679

City: 304 S. Jones Blvd #2432, Las Vegas

State: Nevada (89107)

Country: United States

Website: <https://www.delveinsight.com/consulting>

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/701028569>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.